Polfa Tarchomin S.A
Regulatory Intelligence as a Competitive Advantage in Generic Drug Development
Rafal Lunio
Rafał Łunio is the Director of Research and Development at Polfa Tarchomin S.A. He is responsible for planning, organizing, and directing all operations related to the growth of ongoing pharmaceutical-related research and development of Polfa Tarchomin S.A.
As an R&D Director, He analyzes and helps in developing responses to technical issues and challenges as they arise, and they contributes new ideas to their team related to pharmaceutical research and development. Rafał shared his expertise and valuable thoughts for the 2025 edition of Life Sciences Review Europe.
Regulatory intelligence (RI) can be defined as the process of collecting, analyzing, and applying regulatory information to support strategic decision-making throughout the product lifecycle. In the context of generic drug development, RI plays a critical role in ensuring compliance and building competitive advantage, enabling companies to accelerate market entry, optimize development strategies, and manage regulatory risk more effectively.
In today’s globalized pharmaceutical environment, the complexity of regulatory frameworks across regions makes RI essential. From selecting the optimal regulatory pathway to designing studies aligned with current expectations, informed decisions made early in development can significantly improve both regulatory success and commercial viability.
RI as a Strategic Tool in Development Planning
One of the most impactful applications of RI in the development of generics is early pathway selection. Understanding the latest expectations of regulatory authorities – such as the EMA’s evolving stance on bioequivalence waivers or the FDA’s requirements for complex generics – helps tailor the dossier strategy. In some cases, up-to-date RI may indicate that a BCS-based biowaiver is acceptable for a molecule across multiple regions, eliminating the need for costly bioequivalence studies.
RI also supports the identification of suitable reference medicinal products, clarifies bridging study expectations, and reveals opportunities in less saturated markets. A generic manufacturer seeking registration in both Europe and South America may use RI to design a dossier aligned with differing requirements for stability zones or packaging validation.
Global Intelligence for Regulatory Harmonization and Localization
RI supports global harmonization of submissions (e.g., through the use of CTD format or ICH-aligned studies) and localization strategies where divergent requirements apply. While ICH guidelines form the backbone of regulatory science in many regions, local adaptations exist, stricter excipient justification in parts of Asia, or different expectations for impurity thresholds in Latin America.
Companies that maintain strong RI networks with regional experts and ex-agency professionals are better equipped to anticipate regulatory expectations and avoid costly rejections or delays.
Therefore, effective RI must include up-to-date insights from regional agencies, including unpublished or interpretative positions expressed during scientific advice procedures or local expert meetings. These interactions, whether through direct agency communication or local regulatory consultants, provide a granular context often not captured in formal guidelines. Companies that maintain strong RI networks with regional experts and ex-agency professionals are better equipped to anticipate regulatory expectations and avoid costly rejections or delays.
Monitoring Evolving Guidelines and Trends
An essential function of RI is the continuous monitoring of regulatory evolution. Agencies such as the EMA, FDA, and WHO regularly update or reinterpret existing guidelines in response to scientific progress or public health needs. RI enables early detection of these changes, allowing companies to adapt strategies proactively rather than reactively.
Consider a manufacturer developing a topical generic that identifies a newly released guideline prioritizing Q3 similarity over traditional BE approaches. Integrating that insight early could shift the formulation and in vitro testing strategy, improving the chance of acceptance and avoiding rejection based on outdated assumptions.
Likewise, evolving rules on data protection periods, labeling, or variation procedures can directly influence a product’s market value or launch timing. RI supports companies in mapping such changes and optimizing submission timing, whether by accelerating filing before a policy shift or waiting for more favorable conditions.
Reducing Risk and Avoiding Regulatory Setbacks
RI also plays a key role in minimizing regulatory risk. By analyzing regulatory precedents, agency feedback, and trends in refusals or deficiencies, companies can reduce the likelihood of rejection. Many agencies publish lists of common refusal reasons, which RI teams can study to avoid recurring pitfalls.
As an illustration, insights from previous deficiency letters may indicate that a particular analytical method lacks sufficient sensitivity for inhalation products and is frequently rejected. A proactive developer, equipped with such intelligence, can integrate a more robust method early in development and justify it effectively in Module 3 of the CTD.
Furthermore, RI supports regulatory foresight. By anticipating more stringent expectations, such as those related to nitrosamines or extractables and leachables, companies can implement appropriate controls earlier in the lifecycle. This approach helps to avoid post-approval changes that might delay product launches or increase regulatory and operational costs.
Supporting Cross-Functional Decision-Making and Commercial Success
RI is not solely a regulatory function. When integrated into cross-functional teams—including R&D, QA, and commercial functions—it enables more coherent and forward-looking product strategies. A dossier developed with RI-informed decisions is more likely to meet diverse global requirements, reducing the burden of rework during out-licensing or technology transfer.
From a commercial perspective, a development program guided by RI is positioned for faster approvals, broader geographic reach, and higher partnering attractiveness. Many generic companies rely on dossier sales or license agreements as part of their business model; RI ensures that the technical and regulatory file it prepares meets the expectations of unknown future clients across multiple regions.
Conclusion
Regulatory intelligence is more than a compliance function; it is a strategic enabler that shapes the success of generic drug development. When applied early and consistently, RI reduces uncertainty, informs smarter development decisions, and aligns dossier content with evolving global requirements. As regulatory complexity increases and development timelines tighten, companies that invest in strong RI capabilities will be better positioned to navigate global markets, secure faster approvals, and deliver high-quality generic products with reduced regulatory risk.
